AR114277A1 - ANTI-CD25 ANTIBODY AGENTS - Google Patents
ANTI-CD25 ANTIBODY AGENTSInfo
- Publication number
- AR114277A1 AR114277A1 ARP190100619A ARP190100619A AR114277A1 AR 114277 A1 AR114277 A1 AR 114277A1 AR P190100619 A ARP190100619 A AR P190100619A AR P190100619 A ARP190100619 A AR P190100619A AR 114277 A1 AR114277 A1 AR 114277A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- present disclosure
- antibody agents
- disclosure provides
- antibody sequences
- Prior art date
Links
Abstract
La presente divulgación proporciona secuencias de anticuerpos encontradas en anticuerpos que se unen a CD25 humana. En particular, la presente divulgación proporciona secuencias de anticuerpos anti-CD25 humanos, que no bloquean la unión de CD25 a IL-2 ni la señalización de IL-2. Los anticuerpos y las porciones de unión a antígeno de los mismos que incluyen dichas secuencias se pueden usar en composiciones farmacéuticas y métodos de tratamiento, en particular para tratar el cáncer.The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides human anti-CD25 antibody sequences, which do not block CD25 binding to IL-2 or IL-2 signaling. Antibodies and antigen-binding portions thereof that include such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642218P | 2018-03-13 | 2018-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114277A1 true AR114277A1 (en) | 2020-08-12 |
Family
ID=72291173
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100619A AR114277A1 (en) | 2018-03-13 | 2019-03-13 | ANTI-CD25 ANTIBODY AGENTS |
| ARP190100620A AR114278A1 (en) | 2018-03-13 | 2019-03-13 | ANTI-CD25 ANTIBODY AGENTS |
| ARP190100618A AR114276A1 (en) | 2018-03-13 | 2019-03-13 | ANTI-CD25 ANTIBODY AGENTS |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100620A AR114278A1 (en) | 2018-03-13 | 2019-03-13 | ANTI-CD25 ANTIBODY AGENTS |
| ARP190100618A AR114276A1 (en) | 2018-03-13 | 2019-03-13 | ANTI-CD25 ANTIBODY AGENTS |
Country Status (1)
| Country | Link |
|---|---|
| AR (3) | AR114277A1 (en) |
-
2019
- 2019-03-13 AR ARP190100619A patent/AR114277A1/en unknown
- 2019-03-13 AR ARP190100620A patent/AR114278A1/en unknown
- 2019-03-13 AR ARP190100618A patent/AR114276A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR114278A1 (en) | 2020-08-12 |
| AR114276A1 (en) | 2020-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210287A1 (en) | ANTI-CD25 FOR THE DEPLETION OF SPECIFIC TUMOR CELLS | |
| CL2020001854A1 (en) | Gprc5d binding antibodies. | |
| ECSP18005520A (en) | FACTOR XI ANTIBODIES AND METHODS OF USE | |
| EA201892294A1 (en) | ANTIBODIES AND COMPOSITIONS AGAINST TIM-3 | |
| NI201700018A (en) | ANTI-LAG3 ANTIBODIES AND ANTIGEN BINDING FRAGMENTS | |
| AR107781A1 (en) | BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME | |
| CL2020003071A1 (en) | Multispecific binding proteins and enhancements with them | |
| CO2020014345A2 (en) | Gucy2c-specific antibodies and their uses | |
| NI201700012A (en) | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | |
| EA201890305A1 (en) | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | |
| EA201990296A1 (en) | ANTIBODIES AGAINST SIGLEC-7 FOR CANCER TREATMENT | |
| EA201790719A1 (en) | BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE TO BIND CD19 AND CD3, AND THEIR APPLICATION THEREOF | |
| BR112017006468A2 (en) | bispecific antibody, pharmaceutical composition, kit, use of a combination of a bispecific antibody and cancer treatment method | |
| CO2020013089A2 (en) | Antibodies against mica and / or micb and their uses | |
| MX2018015265A (en) | Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders. | |
| CL2021002603A1 (en) | Anti-cd25 for tumor-specific cell depletion (divisional of application no. 202002340) | |
| BR112021022784A2 (en) | Compositions and methods for cancer treatment | |
| CL2019002735A1 (en) | Antibodies that bind to steap-1. | |
| UY37598A (en) | MIMETIC ANTIBODIES OF FGF21 AND USES OF THE SAME | |
| CL2021002318A1 (en) | Methods of treating amyloidosis by | |
| BR112019023742A2 (en) | anti-trkb antibodies | |
| AR114277A1 (en) | ANTI-CD25 ANTIBODY AGENTS | |
| CO2022003053A2 (en) | Antigen binding proteins | |
| EA202090944A1 (en) | ANTI-CD3-ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING ONCOLOGICAL DISEASES, CONTAINING IT | |
| AR117579A1 (en) | SPECIFIC ANTIBODIES FOR GUCY2C AND ITS USES |